Ionis Pharmaceuticals (NASDAQ: IONS), known as Isis Pharmeceuticals until December 2015, is a publicly traded pharmaceutical company based in Carlsbad, California, United States. It has a single cholesterol-reducing drug in the market and several compounds in the drug pipeline including IONIS-HTTRx, the first intrathecally administered huntingtin-lowering drug for Huntington's disease; and nusinersen (IONIS-SMNRx), an intrathecally administered antisense oligonucleotide drug for spinal muscular atrophy. The company was founded in 1989 by Stanley Crooke, a former GlaxoSmithKline head of research, with a view to commercialize antisense therapy.
Ionis shares plunge as safety crisis deepens, GSK abandons PhIII A few weeks after the FDA slapped a clinical hold on GlaxoSmithKline’s late-stage work on an experimental drug for a rare cardiac condition, the pharma giant has decided to put its plans for a Phase III on a back burner. And in a call with analysts, its development partners at Ionis Pharmaceuticals say those safety issues are related to severe declines in platelets--thrombocytopenia--which also recently appeared unexpectedly among some of the patients enrolled in a separate, ApoCIII trial for another drug called volanesorsen. Read full article here: http://www.fiercebiotech.com/ionis-reveals-safety-issues-two-phiii-studies-after-gsk-delays-a-trial
Shares of Ionis Pharmaceuticals IONS stock soared over 36% on Monday on news that the company’s clinical drug trial for spinal muscular atrophy in infants was successful. The Carlsbad, CA based firm is an RNA-targeted drug discovery and development company which focuses on developing drugs for rare and severe diseases. The company had been working in tandem with partner Biogen BIIB to develop nusinersen, a drug meant to treat spinal muscular atrophy (SMA) in infants. It is a genetic condition that results in the loss of motor neurons in the brain and spine and eventually leads to paralysis.
Ionis Pharmaceuticals's PT raised by Leerink Swann to $47.00. market perform rating. https://www.marketbeat.com/stocks/NASDAQ/IONS/?RegistrationCode=SocialMedia-StockTwits
Shares of Ionis Pharmaceuticals ($IONS) moved notably lower in pre-market trading after the company reported positive results from a trial of its treatment for familial amyloid polyneuropathy but traders expressed concerns about side effects.
